{"name":"Leucid Bio","slug":"leucid-bio","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"LEU011","genericName":"LEU011","slug":"leu011","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"LEU011","genericName":"LEU011","slug":"leu011","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQRXRYQXhXdk44c0M4UTlMZFhCYmRLWjR0bEkxeVd1djk4T3JkN1QyWTU1MVBycGY5Zk0xbGpLcE05OXVfMEpDVXE3a3FEd1VsRnpudjRQcXdWck44dU10NjhmcHdSOERCbk5YdDhRRUQ2THJpSGs5M1cxcGQwM3BmRW93aFRSNjJHa3hYRnRzQk1lTURLdzdLVWk0R2ptTC1wY2ZmemU3TlU1ZkppNU80a1BjeXRDNmZw?oc=5","date":"2026-04-02","type":"regulatory","source":"Multiple Sclerosis News Today","summary":"Quantum Biopharma asks FDA to clear Phase 2 trial of Lucid-MS - Multiple Sclerosis News Today","headline":"Quantum Biopharma asks FDA to clear Phase 2 trial of Lucid-MS","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-01","type":"pipeline","source":"globenewswire.com","summary":"Quantum BioPharma Submits Investigational New Drug (IND) - globenewswire.com","headline":"Quantum BioPharma Submits Investigational New Drug (IND)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOYWZyc0s5dDgydWM3OFVSSWFRVXdHa1ZRNGkxWnE3RTV2aVJpbW9LeW5ZeWRranpZWXNGYUN1WTgwZE9FTWtOdnhIaklNVmZSdlFsbU5EcGZrVXptME9GZWxCTVByQ2MzNnRpTGZEdThxUkJpQ3FQN21JYVJPbVk1Z2hWNDM2am5hY283a25mZzJpOWpaRDdwWUJmQVpJbkRmQkJPUlgwVnBaT1FvVVNTWjY0Sm5mQU1OMWNidVM2Yw?oc=5","date":"2026-04-01","type":"regulatory","source":"Stock Titan","summary":"Quantum BioPharma pushes MS drug toward Phase 2 with FDA filing - Stock Titan","headline":"Quantum BioPharma pushes MS drug toward Phase 2 with FDA filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxOanpHWXI5MFFWX1ZvTzNpaVBJZnRkWk9fS2lSMEJYaWJERXF3UkhlLUtfQmxqR1Buc2FIaGx2TWtwZ2RuT2pPSVBvMGJYeWNMbXZ2TTNVTjN0M0lzeWNmeGxiWkhlVUppTzBMeXdDNmwtdi14bE15ZHV5ZS0yRzItM0JpT2ZQN29oZ0RPWUtvNGFmRmdqMVpZbGtrT3l2WHJlUk5pS1pYMDJuSWw5TUFnUjl1MU1CV1FvSThpUmVFY3FHay1BVW04SF9aR3FOTHNs?oc=5","date":"2026-04-01","type":"regulatory","source":"TipRanks","summary":"Quantum BioPharma Files FDA IND for Phase 2 Trial of Lucid-MS in Multiple Sclerosis - TipRanks","headline":"Quantum BioPharma Files FDA IND for Phase 2 Trial of Lucid-MS in Multiple Sclerosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNdXRLUFpJNEdrTDZMN1VNblNQcDFKVTRHYmplRG5iczFaNUJjSWxNNVFvcndnaVVFSFU2dHpOY1FodHdjTDdKU092bkNlcXVnN2lVNEZoNXl2Y3hSMjJMRE9yR3k2bDQ4ajRWUkxlWWdkT0lDVFJoOFdyRjBWN3JXYnN4eDIyQV9vbjBtVTZiY0JtUmJVX3FYNUdOOUJ6SFl3MWk4ZW9XVjkzdDRKcUEzNDdHTkpRV1B4b1RfSkJDS2pwbGY4ZXc?oc=5","date":"2026-03-30","type":"trial","source":"TipRanks","summary":"Quantum BioPharma Taps Allucent for Phase 2 Trial of Novel MS Drug Lucid-MS - TipRanks","headline":"Quantum BioPharma Taps Allucent for Phase 2 Trial of Novel MS Drug Lucid-MS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTFA5cTlFc0lPUzl4OFkyOEZWWlJVN0RIYjFuSFFka0V3NjlreGRNQWpjSU96QjY4a2h4ZnByMzdJYjM2Q24yU0pNNWNQRFptSWkxMDhsZXFJc0lRYzBpalHSAWNBVV95cUxPNHRucG5PTm93ZThuSjRKekhSSng4S0d1QjNsVFdKam1ZRktNaElodzlSWGZxZHZGbHpoajZXY3N0cVh1a0wwLXFJSHRwb3pXUTBiMWJ3MVoxTG5yb2NWV05PQnM?oc=5","date":"2026-03-26","type":"trial","source":"Bitget","summary":"Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis - Bitget","headline":"Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOb244T25YYWdnMjhPTEdWLW1NZnBra3F4OEZKeWFleGdiRjAyMFhTVzNPdDlJb3ZkVnY1Tkp4V2N6N0F2OGp4UmMxRE8takhDQ1FXa3NZeWpmUDZ2OVU4Y2RIc2F2ZDVwN3Y1WXVDeV8ta1d5YkhRVmh5LWsyY1JDN0sxajFkcFZ0cnRKWFY2aERMei1XeU5ndTNNaGlHTVJ0YUJJbWRwR1hYcElYckhReXFpeG5tNUVpVXc?oc=5","date":"2026-03-26","type":"trial","source":"TipRanks","summary":"Quantum BioPharma Taps MS Expert to Lead Phase 2 Trial of Lucid-MS - TipRanks","headline":"Quantum BioPharma Taps MS Expert to Lead Phase 2 Trial of Lucid-MS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE9KSlMzZl8zZnE5M0ZRSWk1b2NQc0k2cWdMUUgyc0JyNHlTVzFRazg5MTdJY1FtSHdabEpjM3FTeG5KLXRRVElzckxrNmdmTmNKRGJwTWQyeGFoUjk4SnfSAWNBVV95cUxPUXlUOThYWjQ3NDdyUDFYNG5ITGphMndidkZpdVo3VlROQnNma3ZrYWV4cUxlQmhRTzVRWWtYZ1F5LXRweDRRZEF6V0I2dUdBNzZ3ZV9hajVVMTNvZkNOSVNicHc?oc=5","date":"2026-03-25","type":"trial","source":"Bitget","summary":"Quantum BioPharma's Lucid-MS IND Submission: The Pioneering Attempt at Nerve Restoration Approaches Its Crucial Phase 2 Evaluation - Bitget","headline":"Quantum BioPharma's Lucid-MS IND Submission: The Pioneering Attempt at Nerve Restoration Approaches Its Crucial Phase 2 ","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNNFNTcHJkYWxhUE5KRHUxajl3SFFSQ0dZRXc5RTZ6Z3JmeWZUOEl6dzMtaW9CWTdud1lHQlFaNEdUbXFRODhSZDVNa3MtZGkwa3VjSFF2a1M2Ml85NHpkSzc2aTl5aTZOcEhlbElhMU9lZGZ4c0N1YzlJbVcyeGFCRFFVdUh3V3lMRVB6Q3lqY0NHUVlrNTJVdTVZSTQydVJQdWNETHRaVTJDYzRfWHdBZlpBbVVDTFNjVEdBQVpTbw?oc=5","date":"2026-02-06","type":"trial","source":"neurologylive.com","summary":"Myelin Protective Small Molecule Lucid-MS Shows Promising Early-Stage Data in Healthy Volunteers - neurologylive.com","headline":"Myelin Protective Small Molecule Lucid-MS Shows Promising Early-Stage Data in Healthy Volunteers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQLWZEcjNkMEVyYjlORjBBSHZDOXNWQ3N2VG92aHVadVJVWDBSSXpJV0Z4TkZmZVRVRDJuWTE0YUpGM0pMa3FCT0NPaFlFbnlmMWRzaWowMDlONzZVckNWV3pIc1AxRlFWdlhRMTU1d2VneERrRlpNRlhGOV9WamFrUzZsd0FDSUstYXg3RjJoTnNXX3FEVzdJUS1OY1kzajhYZldoeVN0ZjM?oc=5","date":"2025-12-25","type":"trial","source":"The Clinical Trial Vanguard","summary":"Quantum Biopharma Completes Dosing in Lucid-MS Toxicity Study - The Clinical Trial Vanguard","headline":"Quantum Biopharma Completes Dosing in Lucid-MS Toxicity Study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNYVJNZXRwODNXRU51NFlSckprQkZLdl9VaF82ZWI2ZVVUdUM3SWRDWi1LV1lFTGdxSEVjUkZaWllKUERkTEYwekgtbFczZnpuNkJrZ19yV1lpSnVfM1ppNHA1dnRWOS1sdmVwZkY3cmQzNVNmYzBaVTRUbExMcVVZengwSEFyWVNKdmlwWnk2ZDNZdFl6cWc?oc=5","date":"2025-12-23","type":"pipeline","source":"Yahoo Finance","summary":"Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS) - Yahoo Finance","headline":"Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPZVFqbHhhS2JpazNzd05RT2xmbk1ZOFIwRlJteWNVSm53cGdSd1pkY0lfNm9GcVhwUURNc3BMaUJzajlXOXZmWmJRTmkzekx2SWlzS08yQlktZF8xWDgyOFBmTGMxclJVTnYzcXdTVi00d25iSnZ6T1M1R2lJaW1hUUkxdlJXQ0trMUcwSHd3TTNlVzVaRkdKTkZwMFNqWlB4S3otZHBIMVU3eWVNdjlPWWc2MEMxWGMxLVhHSy1DMFI?oc=5","date":"2025-12-23","type":"pipeline","source":"Stock Titan","summary":"Long-term safety tests finish for new multiple sclerosis drug candidate - Stock Titan","headline":"Long-term safety tests finish for new multiple sclerosis drug candidate","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}